An observational study in BPH With Symptomatic Lower Urinary Tract Symptoms, sponsored by ProVerum Medical. Recruiting at 1 site in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by ProVerum Medical · Observational
A study to collect data on the post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.
An analysis of US based subjects who exited from the ProVIDE or ProVIDE II studies.
827 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
This study's planned enrollment of 25 is below the median of 250 across 177 observational studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →ProVerum Medical is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
All US based subjects who exited from the ProVIDE or ProVIDE II studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
US based subjects who exited from the ProVIDE or ProVIDE II studies.
Device: ProVee Urethral Expander System
ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
Also known as: ProVee Expander, ProVee
Post-study exit incidence of secondary reintervention using alternate surgical LUTS therapy.
Time frame: Up to 36 months
Plan to share: No — No plan to make individual participant data (IPD) available to other researchers
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.